A share price of Kyverna Therapeutics Inc [KYTX] is currently trading at $8.99, up 1.24%. An important factor to consider is whether the stock is rising or falling in short-term value. The KYTX shares have gain 30.10% over the last week, with a monthly amount glided 20.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on May 27, 2025, and kept the price target unchanged to $5. On October 10, 2024, UBS initiated with a Buy rating and assigned a price target of $13 on the stock. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $16 on October 09, 2024. H.C. Wainwright initiated its recommendation with a Neutral and recommended $8 as its price target on July 03, 2024. Wells Fargo started tracking with an Overweight rating for this stock on March 04, 2024, and assigned it a price target of $44. In a note dated March 04, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $40 on this stock.
Kyverna Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.78 and $13.67. Currently, Wall Street analysts expect the stock to reach $29.5 within the next 12 months. Kyverna Therapeutics Inc [NASDAQ: KYTX] shares were valued at $8.99 at the most recent close of the market. An investor can expect a potential return of 228.14% based on the average KYTX price forecast.
Analyzing the KYTX fundamentals
Gross Profit Margin for this corporation currently stands at -1.06% with Operating Profit Margin at -84.8%, Pretax Profit Margin comes in at -78.41%, and Net Profit Margin reading is -78.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -0.65 and Total Capital is -0.92. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.76 points at the first support level, and at 8.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.23, and for the 2nd resistance point, it is at 9.46.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kyverna Therapeutics Inc [NASDAQ:KYTX] is 5.16. On the other hand, the Quick Ratio is 5.16, and the Cash Ratio is 1.34.
Transactions by insiders
Recent insider trading involved SEIDENBERG BETH C, Director, that happened on Dec 18 ’25 when 0.13 million shares were purchased. 10% Owner, Westlake BioPartners Opportuni completed a deal on Dec 18 ’25 to buy 0.13 million shares. Meanwhile, Chief Technology Officer Walker Karen Marie sold 23998.0 shares on Dec 15 ’25.
